The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans

Jonathan N. Bauman; Angela C. Doran; Amanda King-Ahmad; Raman Sharma; Gregory S. Walker; Jian Lin; Tsung H Lin; Jean-Baptiste Telliez; Sakambari Tripathy; Theunis C. Goosen; Christopher Banfield; Bimal K Malhotra; Martin E Dowty

doi:10.1124/dmd.122.000829

Article Information

DMD-AR-2022-000829

DOI

https://doi.org/10.1124/dmd.122.000829

Published By

American Society for Pharmacology and Experimental Therapeutics

Print ISSN

0090-9556

Online ISSN

1521-009X

History

Published online June 14, 2022.

© 2020 The Authors. This is an open access article under the terms of the Creative Commons Attribution Non-Commercial License, which permits use, distribution, and reproduction in any medium, provided that the original work is properly cited and is not used for commercial purposes.

Author Information

Jonathan N. Bauman1,
Angela C. Doran2,
Amanda King-Ahmad3,
Raman Sharma4,
Gregory S. Walker5,
Jian Lin6,
Tsung H Lin7,
Jean-Baptiste Telliez7,
Sakambari Tripathy8,
Theunis C. Goosen9,
Christopher Banfield8,
Bimal K Malhotra8, and
Martin E Dowty10,*

¹PDM, Pfizer Global R&D, United States
²Medicine Design - ADME Sciences, Pfizer, United States
³Medicine Design, Pfizer Inc, United States
⁴PDM Biotransformation, Pfizer, United States
⁵PDM, Pfizer, United States
⁶PDM, Pfizer Inc, United States
⁷Inflammation and Immunology, Pfizer Inc, United States
⁸Clinical Pharmacology, Pfizer Inc, United States
⁹Pharmacokinetics, Dynamics & Metabolism, Pfizer, Inc, United States
¹⁰Pfizer Inc, United States

↵* Corresponding Author:
Martin E Dowty, Pfizer Inc, 1 Portland St, Cambridge, Massachusetts, 02139, United States. E-mail: martin.dowty{at}pfizer.com